Of note, ESR1 dependent resistant mechanisms occur in 40.0 % of metastatic (HR)+/HER2- BC patients relapsing from aromatase inhibitor (AI) plus endocrine regimen [5]. This evidence concerns the gene ERBB2 and breast cancer.